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ABSTRACT 
N-acetyl-B-D-glucosaminidase is a lysosomal enzyme made up of two isoenzymes (A and B). It has
been used extensively as a marker for kidney damage. However, its estimation in urine has not been
standardized. We have established a method for the estimation and separation of NAG isoenzymes by
ion-exchange chromatography. In 19 experiments done so far, this method has given reproducible
results. The significance of this method is that with a single experiment, one can estimate total as well
as individual isoenzyme activity. Furthermore, urine constituents do not appear to interfere in this assay
(JPMA 42: 64,1992).
INTRODUCTION 
The monitoring of N-acetyl-B-D-glucosaminidase (NAG; EC 3.2.1.30) in urine is one of the most
promising, early non-invasive tests of renal injury1-4. During the last decade, great efforts have been
made to develop rapid, reliable and cost-effective methods for assay of NAG in urine. All the methods
currently used involve incubation of the enzyme with a phenolic N-acetyl-glucosaminide and can be
divided into two groups. The first group utilizes endpoint methods5-7 in which an alkaline buffer is
added to stop the enzyme reaction and to develop the colour of the released chromogenic phenol
molecule. In contrast, the second group includes several recently developed kinetic rate assays, or
continuous methods8-10, in which the substrate incorporates a phenolic aglycon with a low pICa value
for the free phenol. When the aglycone is released at pH 4.8-6.25, a colour develops, obviating the need
for addition of alkaline-stopping buffer. NAG is now being used in clinical nephrology to detect early
changes of renal functions1-4. but unfortunately it has not been used in our country. In Pakistan,
clinicians are mostly recommending the classical tests, i.e., creatinine clearance or plasma urea to
assess the kidney functions11,12. We have standardized a method for the estimation of total NAG
activity and its isoenzymes in urine.
PATIENTS AND METHODS 
Normal urine was taken from the clinical laboratory Of the Aga Khan University Hospital (AKUR),
Karachi. The urine of the kidney stone patients was taken directly from the patients in the kidney ward.
Some urine samples were also taken from the patients just before and after lithotripsy treatment from
the lithotripsy section of the surgery department. The urine samples were centrifuged for about 10 min
at 5000 rpm and used as such, or frozen at -70°C. Some of the urine samples were also dialyzed against
10 mm sodium phosphate buffer, pH 7.0, for about 24 hrs. NAG-A from human uterus for
standardizing the DEAE-column was partially purified according to the method described elsewhere13.
DEAE-Sepharose column chromatography
One ml urine sample was applied on a minicolumn of DEAE-Sepharose (1.5x3 cm) pre-equilibrated
with 10 mm sodium phosphate buffer, pH 7.0. The flow rate of the column was about 40 mI/hr. The
column was washed with 10 ml equilibrating buffer. The NAG-A was then eluted with 0.3 m NaCl in
equilibrating buffer. 1 ml fraction was taken. The NAG activity was determined in alternate fractions.
NAG activity
The NAG activity in fractions after DEAE-Sepharose chromatography was measured according to the
method described by Severint et al14 by incubating (37°C, 15 min) 0.1 ml fraction with 0.9 ml of 20
mm citrate/phosphate buffer (pH 4.4) containing 0.1 mm methylumbelliferyl glucosaminide. To stop
the reaction, we added 2 ml 0.5 M glycine buffer (pH 10.4). The fluorescence of 4-
methylumbelliferone (4 MU) was measured with Jasco spectrofluorimeter at excitation and emission
wave lengths of 368 and 448 nm, respectively and corrected for blank fluorescence. To calibrate the
method, we used freshly prepared 4 MU standards (in 0.2 M sodium carbonate) of known
concentration. One unit of NAG activity was defined as umole of 4 MU produced/mm under assay
conditions. Total NAG activity was calculated by adding the activities of NAG-A and NAG-B.
RESULTS 
The results of DEAE-Sepharose chromatography of one typical experiment is shown in Figure 1.
This figure shows that NAG-B does not bind with the column while NAG-A is eluted by 0.3 M NaCl as
a single peak. We have estimated the NAG activity in 19 samples of urine from normals and patients.
In all samples NAG-A was always eluted at almost same place. Only two samples (which were from
kidney stone patients) showed NAG-B. In five normal urine samples, only NAG-A was present.
Dialysis of urine has shown no effect on the elution profile of NAG-A. When we calibrated the column
with known amount of NAG-A, we found that the activity in normal urine samples was 2.55± 1.29 U/L
and in stone patients sample was 18.25 U/L (Table).
DISCUSSION 
Increased urinary NAG level is a sensitive biochemical marker of tubular insult and the estimation of
urinary NAG in foreign countries is being used in clinical nephrology to detect early changes of renal
function1-4. However, in Pakistan it has not yet been applied for assessing renal functions. Different
laboratories are using various methods for its estimation in urine5-10. Each method has its own merits
and demerits. For example, p-nitrophenyl N-acetyl-B-D-glucosaminide is a reliable substrate for most
NAG determinations; but because of the colour of the p-nitrophenolate ion is similar to that of urine,
pre- treatment of each urinary specimen by gel filtration has been recommended5. In Japan, Yagi et al9
have synthesized 3, 4- dinitrophenyl N-acetyl-B-Dglucosaminide for direct (continuous) assay of NAG.
However, this substrate is not yet available in the market. Moreover, it is sparingly soluble in water and
the reagent mixture is slightly unstable after dissolution10. Our method for the estimation of NAG in
urine has been found highly reproducible and reliable. There is no problem of interference of
endogenous low-molecular mass activators or inhibitors present in human urine15, because these have
been removed in DEAE-exchange chromatography. The results (Table) clearly showed that kidneys
have been damaged by stones because normal urine samples have very low NAG activity as compared
to stone patients. The main problem is that it is a time consuming method and also it involves
spectrofluorimeter which is a costly equipment and usually not available in many pathology
laboratories. The increased total NAG activity has been associated with renal damage but this method
alone cannot explain the mechanism of damage. A more convenient method is necessary, such as
analysis of NAG isoenzymes in urine14-16. It has been shown that NAG-B increased in urine in
membrane-proliferative glomerulonephritis, focal glomerulosclerosis but not in proliferative
glomerulonephritis or membranous glomerulonephritis. Analysis of NAG isoenzymes has been
performed using DEAE-cellulose column chromatography14. Very recently Shibasaki et al16 have
separated the NAG isoenzymes using automated fast protein liquid chromatography system. HPLC has
also been used for estimation and separation of isoenzymes of NAG17. But these methods are very
expensive. Using linear gradient of NaCl (0-0.3 M) for the elution of NAG from DEAE-column, NAG
has been differentiated into B-, I- and A-forms14,16. We have also used the linear gradient of NaCl (0-
0.5 M) for the elution of NAG from human uterus cytosol (Figure 2)
and we have obtained almost identical results. In the present study our aim was not to differentiate the
NAG isoenzymes. The aim was only to determine the activity of NAG in urine samples of various
kidney diseases. After establishing the method for NAG activity and its isoenzymes in urine, we would
like to apply this methodology for the assessment of renal disease and for monitoring the secondary
involvement of the kidney in disorders such as diabetes, hypertension and rheumatoid arthritis. The
method may also be applied in testing renal functions in the screening of new drugs.
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